Research
CLEC2D orchestrates immune evasion and intrinsic oncogenic signals to fuel triple-negative breast cancer
Nature ·
The Brief
- A Nature Communications-family paper (s42003-026-11357-8) reports that CLEC2D is involved in immune evasion in triple-negative breast cancer.
- The same study describes CLEC2D as contributing to intrinsic oncogenic signalling in this cancer subtype.
- The source material available is a journal feed listing with the title only, so the methods and results are not summarised here.
Why it matters
Triple-negative breast cancer lacks the hormone-receptor and HER2 targets used in other breast cancers, so identifying molecules that help tumours evade immunity and drive growth may point to new research directions.
Who’s affected
- breast cancer researchers
- cancer immunologists
- oncology drug developers
- #breast cancer
- #triple-negative breast cancer
- #immune evasion
- #oncogenic signalling
- #clec2d